Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 02 - 25 save search
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
Published: 2021-02-25 (Crawled : 22:00) - globenewswire.com
BCRX | News | $4.58 -0.65% -0.44% 4.1M
|
Health Technology
|
| O: 3.92%
H: 1.93%
C: -0.92%
positive therapy chmp hereditary angioedema
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
Published: 2021-02-25 (Crawled : 21:03) - globenewswire.com
ASMB | $12.92 -11.02% -12.38% 26K
|
Health Technology
|
| O: -5.71%
H: 6.25%
C: -2.57%
hepatitis therapy injection infections chronic hepatitis b
Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2021-02-25 (Crawled : 15:00) - biospace.com/
EXEL | $22.87 0.22% 0.24% 2.3M
|
Health Technology
|
| O: 0.18%
H: 0.04%
C: -3.26%
treatment therapy cancer breakthrough therapy designation
Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos
Published: 2021-02-25 (Crawled : 13:05) - globenewswire.com
CUE | $1.63 9.03% 8.28% 320K
|
Health Technology
|
| O: 0.07%
H: 3.51%
C: -1.12%
immunotherapy biopharma therapy immunology
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
Published: 2021-02-25 (Crawled : 13:00) - globenewswire.com
ITCI 1 d | $76.69 -3.95% -4.12% 2.3M
|
Health Technology
|
| O: -4.6%
H: 3.93%
C: -1.16%
financial results results therapy
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
Published: 2021-02-24 (Crawled : 00:00) - biospace.com/
BMY | $47.84 -0.87% 0.48% 9.9M
|
Health Technology
|
| O: 0.3%
H: 3.32%
C: 2.78%
BLUE | $0.9633 -2.73% -2.43% 8.4M
|
Health Technology
|
| O: 2.65%
H: 1.48%
C: -1.44%
phase 2 therapy results t-cell car-t cel
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.